Las Vegas Doctor Loses DEA License Over Suspended State Permit
Published Date: 4/16/2025
Notice
Summary
Dr. Ajumobi Agu from Las Vegas lost his DEA license because he kept giving out controlled medicines after his state licenses were suspended. Since he didn’t ask for a hearing, the DEA decided to revoke his registration to keep the public safe. This means he can’t legally handle controlled substances anymore, effective immediately, protecting patients and the community.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
DEA Registration Revoked for Dr. Agu
The DEA revoked Ajumobi Agu, M.D.'s Certificate of Registration No. FA4195459 and denied any pending applications to renew, modify, or add a registration in Nevada. The revocation takes effect May 16, 2025, so Dr. Agu may no longer legally handle controlled substances under that DEA registration.
Public Safety Protected by Revocation
The DEA revoked Dr. Agu's registration to protect patients and the public after finding he issued about 22 controlled-substance prescriptions to 14 patients between June 30, 2023 and September 11, 2023 while his Nevada licenses were suspended. The Order is effective May 16, 2025, and aims to prevent further dispensing of controlled medicines by this registrant in Nevada.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-06451, Lattice-Boom Crawler Cranes (LBCCs) From Japan; Institution of Antidumping Duty Investigation and Scheduling of Preliminary Phase Investigation
The U.S. is starting an investigation to see if cheap lattice-boom crawler cranes from Japan are hurting American crane makers. This could lead to extra taxes on these imports to protect U.S. businesses. The investigation’s first big decision is due by May 27, 2025, with final views sent to the Commerce Department by June 3.
Next: 2025-06453, Victor Augusto Silva, M.D.; Order
Dr. Victor Augusto Silva from Tampa had his DEA registration suspended and then revoked because he let someone else illegally use his license to prescribe drugs. Since he didn’t respond in time to defend himself, the government decided he’s a risk to public safety and took away his registration for good. This means he can’t legally prescribe controlled substances anymore, effective immediately.